159 related articles for article (PubMed ID: 16925149)
21. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Saito M; Tsukuda M
Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
[TBL] [Abstract][Full Text] [Related]
22. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches.
Frame DG
J Support Oncol; 2010; 8(2 Suppl 1):5-9. PubMed ID: 20629452
[TBL] [Abstract][Full Text] [Related]
23. [Gastrointestinal complication of cancer chemotherapy].
Hamaguchi T
Nihon Rinsho; 2007 Oct; 65 Suppl 8():281-6. PubMed ID: 18074549
[No Abstract] [Full Text] [Related]
24. [ESMO 2004. Nausea and vomiting caused by chemotherapy: improving the treatment].
Longo F; Mansueto G
Tumori; 2005; 91(1):suppl 36-48. PubMed ID: 15850022
[No Abstract] [Full Text] [Related]
25. Best practice management of CINV in oncology patients.
;
J Support Oncol; 2010; 8(2 Suppl 1):3-4. PubMed ID: 20629451
[No Abstract] [Full Text] [Related]
26. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Navari RM
Future Oncol; 2010 Jul; 6(7):1073-84. PubMed ID: 20624119
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Moore S; Tumeh J; Wojtanowski S; Flowers C
Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
[TBL] [Abstract][Full Text] [Related]
28. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.
Jordan K; Sippel C; Schmoll HJ
Oncologist; 2007 Sep; 12(9):1143-50. PubMed ID: 17914084
[TBL] [Abstract][Full Text] [Related]
29. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
31. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Hamadani M; Awab A; Chaudhary L; Tfayli A
J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
[No Abstract] [Full Text] [Related]
32. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.
Tageja N; Groninger H
Postgrad Med J; 2016 Jan; 92(1083):34-40. PubMed ID: 26561590
[TBL] [Abstract][Full Text] [Related]
33. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
34. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Grunberg SM; Kris MG
Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 27):1-14; quiz 15-6. PubMed ID: 22362372
[TBL] [Abstract][Full Text] [Related]
35. New drug helps relieve chemotherapy-related symptoms.
FDA Consum; 2003; 37(4):3. PubMed ID: 12971326
[No Abstract] [Full Text] [Related]
36. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
37. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
38. The nurse's role in managing chemotherapy-induced nausea and vomiting: an international survey.
Krishnasamy M; Kwok-Wei So W; Yates P; de Calvo LE; Annab R; Wisniewski T; Aranda S
Cancer Nurs; 2014; 37(4):E27-35. PubMed ID: 24145248
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced nausea and vomiting.
Hesketh PJ
N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
